Cargando…

Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer

AIM: To investigate human epidermal growth factor 2 (HER2) overexpression and validate its prognostic effect in stage II-III gastric cancer. METHODS: We reviewed the data of patients who were diagnosed with gastric cancer between March 2008 and October 2013 at the Yonsei University Medical Center. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Jang Ho, Lim, Jae Yun, Cho, Jae Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685846/
https://www.ncbi.nlm.nih.gov/pubmed/29151694
http://dx.doi.org/10.3748/wjg.v23.i41.7407
_version_ 1783278689187790848
author Cho, Jang Ho
Lim, Jae Yun
Cho, Jae Yong
author_facet Cho, Jang Ho
Lim, Jae Yun
Cho, Jae Yong
author_sort Cho, Jang Ho
collection PubMed
description AIM: To investigate human epidermal growth factor 2 (HER2) overexpression and validate its prognostic effect in stage II-III gastric cancer. METHODS: We reviewed the data of patients who were diagnosed with gastric cancer between March 2008 and October 2013 at the Yonsei University Medical Center. Among these patients, 384 patients who met the inclusion criteria were analyzed retrospectively. RESULTS: Thirty-two (8.3%) of the 384 stage II-III gastric cancer patients exhibited HER2 overexpression. The median follow-up duration was 26.0 mo. HER2-negative patients had superior recurrence-free survival (RFS) compared to HER2-positive patients (HR = 0.52, 95%CI: 0.30-0.89; P = 0.015). The median overall survival (OS) was significantly prolonged in the HER2-negative group compared with the HER2-positive group (55.0 mo vs 38.0 mo, HR = 0.43, 95%CI: 0.21-0.88, P = 0.021). OS was also prolonged in HER2-negative patients who received adjuvant chemotherapy compared to HER2-positive patients (55.0 vs 38.0 mo, HR = 0.42, 95%CI: 0.18-1.00, P = 0.051). In patients who did not receive adjuvant chemotherapy, the median RFS was prolonged in the HER2-negative group compared to the HER2-positive group (not reached vs 12.0 mo, HR = 0.17, 95%CI: 0.06-0.49, P = 0.001). In a multivariate analysis, HER2 status (HR = 0.421, 95%CI: 0.206-0.861, P = 0.018) and Eastern Cooperative Oncology Group performance status (HR = 2.002, 95%CI: 1.530-2.618, P < 0.001) were independent predictors of OS. CONCLUSION: Our findings showed that HER2-positive patients had inferior OS and RFS. Stage II-III HER2-positive patients might be potential candidates for targeted therapies involving trastuzumab.
format Online
Article
Text
id pubmed-5685846
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-56858462017-11-17 Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer Cho, Jang Ho Lim, Jae Yun Cho, Jae Yong World J Gastroenterol Retrospective Study AIM: To investigate human epidermal growth factor 2 (HER2) overexpression and validate its prognostic effect in stage II-III gastric cancer. METHODS: We reviewed the data of patients who were diagnosed with gastric cancer between March 2008 and October 2013 at the Yonsei University Medical Center. Among these patients, 384 patients who met the inclusion criteria were analyzed retrospectively. RESULTS: Thirty-two (8.3%) of the 384 stage II-III gastric cancer patients exhibited HER2 overexpression. The median follow-up duration was 26.0 mo. HER2-negative patients had superior recurrence-free survival (RFS) compared to HER2-positive patients (HR = 0.52, 95%CI: 0.30-0.89; P = 0.015). The median overall survival (OS) was significantly prolonged in the HER2-negative group compared with the HER2-positive group (55.0 mo vs 38.0 mo, HR = 0.43, 95%CI: 0.21-0.88, P = 0.021). OS was also prolonged in HER2-negative patients who received adjuvant chemotherapy compared to HER2-positive patients (55.0 vs 38.0 mo, HR = 0.42, 95%CI: 0.18-1.00, P = 0.051). In patients who did not receive adjuvant chemotherapy, the median RFS was prolonged in the HER2-negative group compared to the HER2-positive group (not reached vs 12.0 mo, HR = 0.17, 95%CI: 0.06-0.49, P = 0.001). In a multivariate analysis, HER2 status (HR = 0.421, 95%CI: 0.206-0.861, P = 0.018) and Eastern Cooperative Oncology Group performance status (HR = 2.002, 95%CI: 1.530-2.618, P < 0.001) were independent predictors of OS. CONCLUSION: Our findings showed that HER2-positive patients had inferior OS and RFS. Stage II-III HER2-positive patients might be potential candidates for targeted therapies involving trastuzumab. Baishideng Publishing Group Inc 2017-11-07 2017-11-07 /pmc/articles/PMC5685846/ /pubmed/29151694 http://dx.doi.org/10.3748/wjg.v23.i41.7407 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Cho, Jang Ho
Lim, Jae Yun
Cho, Jae Yong
Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer
title Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer
title_full Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer
title_fullStr Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer
title_full_unstemmed Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer
title_short Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer
title_sort survival analysis based on human epidermal growth factor 2 status in stage ii-iii gastric cancer
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685846/
https://www.ncbi.nlm.nih.gov/pubmed/29151694
http://dx.doi.org/10.3748/wjg.v23.i41.7407
work_keys_str_mv AT chojangho survivalanalysisbasedonhumanepidermalgrowthfactor2statusinstageiiiiigastriccancer
AT limjaeyun survivalanalysisbasedonhumanepidermalgrowthfactor2statusinstageiiiiigastriccancer
AT chojaeyong survivalanalysisbasedonhumanepidermalgrowthfactor2statusinstageiiiiigastriccancer